Share on StockTwits

Aegerion Pharmaceuticals (NASDAQ:AEGR) announced its earnings results on Tuesday. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.08, American Banking News reports. The company had revenue of $36.00 million for the quarter, compared to the consensus estimate of $35.40 million. During the same quarter in the previous year, the company posted ($0.66) earnings per share. The company’s revenue for the quarter was up 453.8% on a year-over-year basis.

Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) traded up 1.83% on Tuesday, hitting $30.62. 1,689,592 shares of the company’s stock traded hands. Aegerion Pharmaceuticals has a 1-year low of $26.25 and a 1-year high of $101.00. The stock’s 50-day moving average is $31.34 and its 200-day moving average is $44.14. The company’s market cap is $902.7 million.

A number of research firms have recently commented on AEGR. Analysts at Zacks reiterated a “neutral” rating on shares of Aegerion Pharmaceuticals in a research note on Wednesday, July 16th. They now have a $29.00 price target on the stock. On a related note, analysts at Goldman Sachs initiated coverage on shares of Aegerion Pharmaceuticals in a research note on Tuesday, May 27th. They set a “sell” rating and a $27.00 price target on the stock. Finally, analysts at Citigroup Inc. downgraded shares of Aegerion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. Aegerion Pharmaceuticals presently has an average rating of “Hold” and an average target price of $71.10.

Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.